This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of July 2024. See the about page for more details. Also of interest: pageview data on analytics.vipulnaik.com, tutorial in README, request for feedback to EA Forum.
| Item | Value |
|---|---|
| Country | United States |
| Wikipedia page | https://en.wikipedia.org/wiki/Bill_%26_Melinda_Gates_Foundation |
| Best overview URL | https://en.wikipedia.org/wiki/Bill_%26_Melinda_Gates_Foundation |
| Facebook username | gatesfoundation |
| LinkedIn username | bill-&-melinda-gates-foundation |
| Website | https://www.gatesfoundation.org/ |
| Donations URL | https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database |
| Twitter username | gatesfoundation |
| Page on philosophy informing donations | https://www.gatesfoundation.org/What-We-Do |
| Grant application process page | https://www.gatesfoundation.org/How-We-Work/General-Information/Grantseeker-FAQ |
| Regularity with which donor updates donations data | continuous updates |
| Regularity with which Donations List Website updates donations data (after donor update) | irregular |
| Lag with which donor updates donations data | months |
| Lag with which Donations List Website updates donations data (after donor update) | years |
| Data entry method on Donations List Website | SQL insertion commands generated by script https://github.com/riceissa/gates-foundation-iati-processing |
Brief history: The Gates Foundation launched in 2000, with precursors starting in the 1990s, financed by the personal wealth of co-founder Bill Gates from Microsoft. Starting 2005, it scaled up its giving significantly after a large funding commitment from Warren Buffett
Brief notes on broad donor philosophy and major focus areas: See https://www.gatesfoundation.org/Who-We-Are/General-Information/Foundation-Factsheet for the grantmaking areas. The four grantmaking areas are the Global Development Program, Global Health Program, Global Policy and Advocacy, and United States Program. Within the United States Program the focus is on K-12 education, the Internet, and emergency relief
Notes on grant publication logistics: Although the Gates Foundation has a grants database on its website, as well as individual grant pages for every grant, we use the IATI data instead, because it can be processed programmatically (the data on the site does not allow for full data download or easy programmatic processing). This leads to a few problems: first, IATI data does not include grants made in the United States, since it focuses on development assistance (DA) spending. Second, IATI data is updated more infrequently. Third, it may sometimes omit some information that is present in the grants database
Full donor page for donor Bill and Melinda gates Foundation
| Item | Value |
|---|---|
| Country |
Full donee page for donee PATH Vaccine Solutions
| Item | Value |
|---|
| Cause area | Count | Median | Mean | Minimum | 10th percentile | 20th percentile | 30th percentile | 40th percentile | 50th percentile | 60th percentile | 70th percentile | 80th percentile | 90th percentile | Maximum |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | 69 | 1,204,652 | 6,618,436 | -24,498,678 | 0 | 0 | 0 | 297,437 | 1,204,652 | 2,293,091 | 3,796,149 | 10,637,500 | 29,995,199 | 75,000,000 |
| Global health | 69 | 1,204,652 | 6,618,436 | -24,498,678 | 0 | 0 | 0 | 297,437 | 1,204,652 | 2,293,091 | 3,796,149 | 10,637,500 | 29,995,199 | 75,000,000 |
If you hover over a cell for a given cause area and year, you will get a tooltip with the number of donees and the number of donations.
Note: Cause area classification used here may not match that used by donor for all cases.
| Cause area | Number of donations | Total | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global health (filter this donor) | 69 | 456,672,068.83 | -32,347,195.00 | -21,374,847.07 | -7,914,651.62 | 25,434,316.00 | 58,208,009.52 | 75,179,044.00 | 91,504,283.00 | 22,108,845.00 | 30,988,572.00 | 29,995,199.00 | 88,750,000.00 | 96,140,494.00 |
| Total | 69 | 456,672,068.83 | -32,347,195.00 | -21,374,847.07 | -7,914,651.62 | 25,434,316.00 | 58,208,009.52 | 75,179,044.00 | 91,504,283.00 | 22,108,845.00 | 30,988,572.00 | 29,995,199.00 | 88,750,000.00 | 96,140,494.00 |
Graph of spending by cause area and year (incremental, not cumulative)
Graph of spending by cause area and year (cumulative)
There are no documents associated with this combination of donor and donee.
Graph of all donations (with known year of donation), showing the timeframe of donations
| Amount (current USD) | Amount rank (out of 69) | Donation date | Cause area | URL | Influencer | Notes |
|---|---|---|---|---|---|---|
| -24,498,678.00 | 69 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to reduce the number of deaths and hospitalizations of infants due to pneumonia and invasive pneumococcal disease (IPD) in the developing world by advancing the development of safe, effective and affordable new vaccines against S. pneumoniae; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 2,985,848.00 | 24 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to accelerate the development of vaccines against many of the world's most important infectious diseases through the application of controlled human infection models (CHIM); Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -1,695,353.00 | 60 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to develop a controlled human infection model employing a standardized and stable Enterotoxigenic Escherichia coli (ETEC) strain expressing CS6 antigen to accelerate vaccine development for use in developing countries; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -8,944,012.00 | 67 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance clinical development of a late-stage rotavirus vaccine candidate by a developing-country manufacturer, ultimately increasing affordability and access to sustainable rotavirus vaccine introduction in low-resource settings; and to conduct additio; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -27,865.50 | 50 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to provide technical assistance to the Vaccine Product Acceleration Network (V-PAN) that was discussed at the 2013 Global Health Product Development Forum in Seattle, Washington. Specifically, PATH Vaccine Solutions (PVS) will audit and assess Chemistry, ; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified|South of Sahara. | |
| -167,134.50 | 55 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to provide technical assistance to the Vaccine Product Acceleration Network (V-PAN) that was discussed at the 2013 Global Health Product Development Forum in Seattle, Washington. Specifically, PATH Vaccine Solutions (PVS) will audit and assess Chemistry, ; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified|South of Sahara. | |
| -5,930,956.00 | 65 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to protect infants through RSV maternal immunization. RSV Vaccine Project – protecting young infants through maternal immunization. Investment start date: 11/19/2013 to end date: 12/31/2020. Grantee name: PATH Vaccine Solutions; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 297,437.00 | 42 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to establish an international standard for both manufacturers and regulators of Sabin Inactivated Polio Vaccine as they proceed down the development pathway to licensure and WHO Pre-qualification; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -1,003,830.00 | 59 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance early clinical development of the bovine-human reassortant rotavirus strains (BRV) candidate ultimately expanding the global rotavirus vaccine market to increase affordability and improve access; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified. | |
| -12,409,973.00 | 68 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to reduce the morbidity and mortality rates among infants and children in the developing world due to diarrheal disease by advancing the development of safe, affordable, and efficacious new vaccines to prevent the leading bacterial causes of diarrhea, ETE; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -109,178.06 | 53 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support activities of the phase IV trials, coordinating the complex lab support/assay related activities, and develop an product development plan for nOPV; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -87,574.12 | 52 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to explore development of a nimble and focused experimental medicine (EM) approach to vaccine research; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -3,103,132.89 | 62 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance the development and introduction of promising new rotavirus vaccine candidates; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 972,360.00 | 37 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to assist developing-country vaccine manufacturers (DCVMs) in establishing effective auditing and compliance systems through on-site inspections, mentoring, and training activities; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified. | |
| -475,790.00 | 57 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance the development of two vaccine components potentially useful for preventing diseases common in low-resource countries using a technology that should make them available in higher quantities and at lower costs; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -120,861.96 | 54 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to provide technical assistance to the Vaccine Product Acceleration Network (V-PAN) that was discussed at the 2013 Global Health Product Development Forum in Seattle, Washington. Specifically, PATH Vaccine Solutions (PVS) will audit and assess Chemistry, ; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified|South of Sahara. | |
| -724,918.04 | 58 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to provide technical assistance to the Vaccine Product Acceleration Network (V-PAN) that was discussed at the 2013 Global Health Product Development Forum in Seattle, Washington. Specifically, PATH Vaccine Solutions (PVS) will audit and assess Chemistry, ; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified|South of Sahara. | |
| -6,000,000.00 | 66 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance the development and introduction of promising new rotavirus vaccine candidates; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 150,814.00 | 45 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to reduce severe illness and death among infants and children by evaluating non-replicating rotavirus vaccine candidates as viable alternatives to oral, live attenuated rotavirus vaccines; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -2,254,011.00 | 61 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance the development and introduction of promising new rotavirus vaccine candidates; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 1,436,522.00 | 32 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support an assessment of the feasibility and resource requirements for developing a group B streptococcus vaccine; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -3,908,871.00 | 64 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance clinical development of second-generation rotavirus vaccine candidates by developing-country manufacturers, increasing global competitiveness of the products and improving access to sustainable rotavirus vaccine introduction; Aid type: Project-type interventions. Affected countries: India. | |
| 4,009,536.00 | 20 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to reduce severe illness and death among infants and children by evaluating non-replicating rotavirus vaccine candidates as viable alternatives to oral, live attenuated rotavirus vaccines; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -27,071.62 | 49 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support the participation of key investigators at an international conference on new developments in the field of vaccines for enteric diseases that are of global public health significance; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 4,999,738.00 | 16 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to accelerate the development of vaccines against many of the world's most important infectious diseases through the application of controlled human infection models (CHIM); Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 2,799,108.00 | 26 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to develop a controlled human infection model employing a standardized and stable Enterotoxigenic Escherichia coli (ETEC) strain expressing CS6 antigen to accelerate vaccine development for use in developing countries; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 11,946,434.00 | 13 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to reduce the morbidity and mortality rates among infants and children in the developing world due to diarrheal disease by advancing the development of safe, affordable, and efficacious new vaccines to prevent the leading bacterial causes of diarrhea, ETE; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 2,999,845.00 | 23 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to establish an international standard for both manufacturers and regulators of Sabin Inactivated Polio Vaccine as they proceed down the development pathway to licensure and WHO Pre-qualification; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 1,204,652.00 | 35 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to convene developing country vaccine manufacturers for a series of meetings that will contribute to the accelerated development and introduction of safe, affordable, and accessible rotavirus vaccines for use in the public sector of high-burden developing; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 1,372,057.00 | 34 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support activities of the phase IV trials, coordinating the complex lab support/assay related activities, and develop an product development plan for nOPV; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 22,546.65 | 47 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to reduce the number of deaths and hospitalizations of infants due to pneumonia and invasive pneumococcal disease (IPD) in the developing world by advancing the development of safe, effective and affordable new vaccines against S. pneumoniae; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -22,546.65 | 48 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support a portfolio of pneumococcal vaccine projects. A Portfolio of Pneumococcal Vaccine Projects. Investment start date: 3/1/2006 to end date: 10/5/2015. Grantee name: PATH Vaccine Solutions; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 112,482.00 | 46 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support the participation of key investigators at an international conference on new developments in the field of vaccines for enteric diseases that are of global public health significance; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 2,293,091.00 | 28 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance the development and evaluation of the promising new dmLT adjuvant by ensuring an expanded supply of high-quality clinical-grade material for use in trials designed to further investigate its ability to improve the immunogenicity and protective ; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 344,888.00 | 41 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to explore development of a nimble and focused experimental medicine (EM) approach to vaccine research; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -322,743.56 | 56 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to examine the etiology of cases of diarrhea at one rotavirus vaccine clinical trial site in India in order to gather data that will help establish priorities for future enteric vaccine development; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 3,796,149.00 | 21 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance early clinical development of the bovine-human reassortant rotavirus strains (BRV) candidate ultimately expanding the global rotavirus vaccine market to increase affordability and improve access; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified. | |
| 4,197,230.00 | 19 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance the development of two vaccine components potentially useful for preventing diseases common in low-resource countries using a technology that should make them available in higher quantities and at lower costs; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 49,348,905.00 | 4 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to reduce the morbidity and mortality rates among infants and children in the developing world due to diarrheal disease by advancing the development of safe, affordable, and efficacious new vaccines to prevent the leading bacterial causes of diarrhea, ETE; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -3,261,753.00 | 63 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to examine the etiology of cases of diarrhea at one rotavirus vaccine clinical trial site in India in order to gather data that will help establish priorities for future enteric vaccine development; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 399,927.00 | 38 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support an assessment of the feasibility and resource requirements for developing a group B streptococcus vaccine; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 1,447,117.00 | 31 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to accelerate the development of high-quality and low-cost polio vaccines needed in the peri- and post-eradication era; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| -34,800.92 | 51 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | To support the Respiratory Syncytial Virus (RSV) Vaccine Forum and Live Attenuated Influenza Vaccine (LAIV) Clinical Data Review Meeting; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 3,661,753.00 | 22 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to examine the etiology of cases of diarrhea at one rotavirus vaccine clinical trial site in India in order to gather data that will help establish priorities for future enteric vaccine development; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 2,500,000.00 | 27 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to reduce morbidity and mortality among infants and children in the developing world due to influenza, both seasonal and pandemic, by advancing the development of safe, effective, and affordable new vaccines against influenza virus that are suitable for u; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 29,689,895.00 | 8 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to protect infants through RSV maternal immunization. RSV Vaccine Project – protecting young infants through maternal immunization. Investment start date: 11/19/2013 to end date: 12/31/2020. Grantee name: PATH Vaccine Solutions; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 2,819,689.00 | 25 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to assist developing-country vaccine manufacturers (DCVMs) in establishing effective auditing and compliance systems through on-site inspections, mentoring, and training activities; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified. | |
| 363,444.00 | 40 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to provide technical assistance to the Vaccine Product Acceleration Network (V-PAN) that was discussed at the 2013 Global Health Product Development Forum in Seattle, Washington. Specifically, PATH Vaccine Solutions (PVS) will audit and assess Chemistry, ; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified|South of Sahara. | |
| 2,179,901.00 | 30 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to provide technical assistance to the Vaccine Product Acceleration Network (V-PAN) that was discussed at the 2013 Global Health Product Development Forum in Seattle, Washington. Specifically, PATH Vaccine Solutions (PVS) will audit and assess Chemistry, ; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified|South of Sahara. | |
| 8,000,000.00 | 15 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to develop safe, effective, and affordable vaccines for introduction into the developing world; Aid type: Other technical assistance. Affected regions: Developing countries, unspecified. | |
| 198,725.00 | 43 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to assess the dengue vaccine development efforts underway at Chengdu Institute of Biological Products (CDIBP); Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 189,840.00 | 44 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | To support the Respiratory Syncytial Virus (RSV) Vaccine Forum and Live Attenuated Influenza Vaccine (LAIV) Clinical Data Review Meeting; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 10,637,500.00 | 14 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance clinical development of a late-stage rotavirus vaccine candidate by a developing-country manufacturer, ultimately increasing affordability and access to sustainable rotavirus vaccine introduction in low-resource settings; and to conduct additio; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 14,938,297.00 | 12 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to accelerate the development of safe, affordable, and efficacious new vaccines to reduce the morbidity and mortality caused by ETEC and Shigella in infants and young children in the developing world; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 59,570,401.00 | 2 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to reduce the number of deaths and hospitalizations of infants due to pneumonia and invasive pneumococcal disease (IPD) in the developing world by advancing the development of safe, effective and affordable new vaccines against S. pneumoniae; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 4,892,727.00 | 18 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance clinical development of second-generation rotavirus vaccine candidates by developing-country manufacturers, increasing global competitiveness of the products and improving access to sustainable rotavirus vaccine introduction; Aid type: Project-type interventions. Affected countries: India. | |
| 26,666,502.00 | 9 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | To support efforts to develop a low-cost polysaccharide conjugate vaccine against Streptococcus pneumoniae to reduce childhood morbidity and mortality from lower respiratory infections in low-income regions.; Aid type: Project-type interventions. Affected countries: India. | |
| 374,653.00 | 39 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to assess the capacity of six China National Biotec Group institutes to meet World Health Organization requirements for priority vaccines, to improve their potential to provide safe, effective, and affordable vaccines; Aid type: Other technical assistance. Affected countries: China. | |
| 1,408,325.00 | 33 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to assess the capacity of six China National Biotec Group institutes to meet World Health Organization requirements for priority vaccines, to improve their potential to provide safe, effective, and affordable vaccines; Aid type: Other technical assistance. Affected countries: China. | |
| 15,740,726.00 | 11 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to reduce severe illness and death among infants and children by evaluating non-replicating rotavirus vaccine candidates as viable alternatives to oral, live attenuated rotavirus vaccines; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 4,959,794.00 | 17 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to accelerate the development of high-quality and low-cost polio vaccines needed in the peri- and post-eradication era; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 29,999,216.00 | 6 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance clinical development of a late-stage rotavirus vaccine candidate by a developing-country manufacturer, ultimately increasing affordability and access to sustainable rotavirus vaccine introduction in low-resource settings; and to conduct additio; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 989,356.00 | 36 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support planning and preparations for bioprocess, formulation, and early clinical development of non-replicating rotavirus vaccines; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 29,995,199.00 | 7 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to advance the development and introduction of promising new rotavirus vaccine candidates; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 38,750,000.00 | 5 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support research and development of new influenza vaccines to address pandemic influenza; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 50,000,000.00 | 3 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to develop Shigella and ETEC vaccines that induce potent, broadly reactive, and persistent immunity and are effective in preventing disease in populations most at risk, especially young children; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified; affected countries: Kenya|Cambodia|Viet nam. | |
| 2,182,670.00 | 29 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to conduct a landscape analysis of potential pandemic flu vaccine technologies. Pandemic flu vaccine project. Investment start date: 11/12/2006 to end date: 12/31/2007. Grantee name: PATH Vaccine Solutions; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 18,957,824.00 | 10 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to accelerate the development of a safe, affordable and efficacious rotavirus vaccine for the developing world; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. | |
| 75,000,000.00 | 1 | Global health/infectious disease control | https://iatiregistry.org/publisher/bmgf | -- | to support a portfolio of pneumococcal vaccine projects. A Portfolio of Pneumococcal Vaccine Projects. Investment start date: 3/1/2006 to end date: 10/5/2015. Grantee name: PATH Vaccine Solutions; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |